Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
STXS Stock Forecast 2026-2027
$1.92
Current Price
$187.16M
Market Cap
Buy 5
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to STXS Price Targets
+160.4%
To High Target of $5.00
+108.3%
To Median Target of $4.00
+108.3%
To Low Target of $4.00
STXS Price Momentum
-4.5%
1 Week Change
+7.3%
1 Month Change
-3.5%
1 Year Change
-16.5%
Year-to-Date Change
-46.5%
From 52W High of $3.59
+10.3%
From 52W Low of $1.74
📊 TOP ANALYST CALLS
Did STXS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Stereotaxis is one of their latest high-conviction picks.
Latest STXS Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, STXS has a bullish consensus with a median price target of $4.00 (ranging from $4.00 to $5.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $1.92, the median forecast implies a 108.3% upside. This outlook is supported by 5 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Wittes at Roth MKM, projecting a 160.4% upside. Conversely, the most conservative target is provided by Kyle Bauser at Roth Capital, suggesting a 108.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
STXS Analyst Ratings
5
Buy
0
Hold
0
Sell
STXS Price Target Range
Low
$4.00
Average
$4.00
High
$5.00
Current: $1.92
Latest STXS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for STXS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 16, 2025 | Citizens | Market Outperform | Initiates | $N/A | |
| Nov 12, 2025 | Roth Capital | Kyle Bauser | Buy | Reiterates | $4.00 |
| Nov 5, 2025 | Roth Capital | Kyle Bauser | Buy | Reinstates | $4.00 |
| Mar 5, 2024 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Mar 5, 2024 | Roth MKM | Jason Wittes | Buy | Reiterates | $5.00 |
| Jan 10, 2024 | Roth MKM | Jason Wittes | Buy | Initiates | $5.00 |
| Mar 6, 2023 | B. Riley Securities | Neil Chatterji | Buy | Maintains | $5.50 |
| Mar 6, 2023 | Piper Sandler | Adam Maeder | Overweight | Maintains | $5.00 |
| Mar 6, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $4.00 |
| Nov 11, 2022 | Cowen & Co. | Joshua Jennings | Outperform | Maintains | $5.00 |
| Sep 2, 2022 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jul 12, 2022 | Aegis Capital | Nathan Weinstein | Buy | Initiates | $6.00 |
| Jun 23, 2022 | B. Riley Securities | Buy | Initiates | $N/A | |
| Jan 5, 2022 | Craig-Hallum | Buy | Initiates | $N/A | |
| Jan 5, 2022 | Loop Capital | Buy | Initiates | $N/A | |
| May 26, 2021 | Piper Sandler | Overweight | Initiates | $N/A | |
| Sep 8, 2020 | Northland Capital Markets | Outperform | Initiates | $N/A | |
| Apr 9, 2020 | Cowen & Co. | Outperform | Initiates | $N/A |
Stereotaxis Inc. (STXS) Competitors
The following stocks are similar to Stereotaxis based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
STXS
Stereotaxis
mkt cap
197.88M
Stereotaxis Inc. (STXS) Financial Data
Stereotaxis Inc. has a market capitalization of $187.16M with a P/E ratio of -7.9x. The company generates $32.38M in trailing twelve-month revenue with a -66.8% profit margin.
Revenue growth is +36.3% quarter-over-quarter, while maintaining an operating margin of -61.2% and return on equity of -143.6%.
Valuation Metrics
Market Cap
$187.16M
Enterprise Value
$183.97M
P/E Ratio
-7.9x
PEG Ratio
0.2x
Price/Sales
5.8x
Growth & Margins
Revenue Growth (YoY)
+36.3%
Gross Margin
+50.1%
Operating Margin
-61.2%
Net Margin
-66.8%
EPS Growth
+36.3%
Financial Health
Cash/Price Ratio
+7.2%
Current Ratio
1.5x
Debt/Equity
29.0x
ROE
-143.6%
ROA
-25.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Stereotaxis Inc. (STXS) Business Model
About Stereotaxis Inc.
What They Do
Develops robotic systems for minimally invasive surgery.
Business Model
The company generates revenue primarily through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System. This system is designed to enhance the precision and efficiency of cardiac arrhythmia treatments, thereby attracting hospitals and medical centers to adopt its technology, which improves patient outcomes and operational workflows.
Additional Information
Stereotaxis is based in St. Louis, Missouri, and is positioned to contribute significantly to the growth and innovation of the medical device market, especially in the field of robotic surgery.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
139
CEO
Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
Country
United States
IPO Year
2004
Website
www.stereotaxis.comStereotaxis Inc. (STXS) Latest News & Analysis
Latest News
Quick Summary
Stereotaxis (NYSE: STXS) will release Q1 2026 financial results on May 12, 2026, after market close, followed by a conference call at 4:30 p.m. EST to discuss the results.
Why It Matters
Stereotaxis' upcoming earnings release and conference call may influence investor sentiment and stock price, providing insights into its financial health and strategic direction in surgical robotics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) reported the successful treatment of the first US patients using its MAGiC™ surgical robotics system for minimally invasive endovascular procedures.
Why It Matters
Successful treatment of patients using MAGiC™ enhances Stereotaxis's market position, potentially boosting sales and investor confidence in future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis acquires Robocath to enhance its robotic surgery capabilities and develop a comprehensive endovascular platform, targeting growth opportunities.
Why It Matters
Stereotaxis's acquisition of Robocath signals strategic growth in robotic surgery, potentially enhancing market position and revenue streams, attracting investor interest in future profitability.
Source: Zacks Investment Research
Market Sentiment:
Positive
Stereotaxis, Inc. (STXS) M&A Call Transcript
7 days ago
Quick Summary
Stereotaxis, Inc. (STXS) held a call discussing mergers and acquisitions, providing insights into their strategic plans and potential growth opportunities.
Why It Matters
M&A activity often signals strategic growth potential, impacting stock valuation and investor sentiment. Stereotaxis' plans could influence market positioning and future profitability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) has announced its acquisition of Robocath, a company specializing in robotic technologies for interventional cardiology and neurointerventions.
Why It Matters
Stereotaxis's acquisition of Robocath expands its technological capabilities in surgical robotics, potentially enhancing market share and driving future revenue growth in a competitive healthcare sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Stereotaxis (NYSE: STXS) has received FDA 510(k) clearance for its Synchrony™ system, enhancing its position in surgical robotics for minimally invasive endovascular procedures.
Why It Matters
FDA clearance for the Synchrony™ system enhances Stereotaxis's market position, potentially boosting revenue and investor confidence in future growth prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About STXS Stock
What is Stereotaxis Inc.'s (STXS) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Stereotaxis Inc. (STXS) has a median price target of $4.00. The highest price target is $5.00 and the lowest is $4.00.
Is STXS stock a good investment in 2026?
According to current analyst ratings, STXS has 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.92. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for STXS stock?
Wall Street analysts predict STXS stock could reach $4.00 in the next 12 months. This represents a 108.3% increase from the current price of $1.92. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Stereotaxis Inc.'s business model?
The company generates revenue primarily through the development and commercialization of its robotic navigation technologies, particularly the Niobe Magnetic Navigation System. This system is designed to enhance the precision and efficiency of cardiac arrhythmia treatments, thereby attracting hospitals and medical centers to adopt its technology, which improves patient outcomes and operational workflows.
What is the highest forecasted price for STXS Stereotaxis Inc.?
The highest price target for STXS is $5.00 from Jason Wittes at Roth MKM, which represents a 160.4% increase from the current price of $1.92.
What is the lowest forecasted price for STXS Stereotaxis Inc.?
The lowest price target for STXS is $4.00 from Kyle Bauser at Roth Capital, which represents a 108.3% increase from the current price of $1.92.
What is the overall STXS consensus from analysts for Stereotaxis Inc.?
The overall analyst consensus for STXS is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $4.00.
How accurate are STXS stock price projections?
Stock price projections, including those for Stereotaxis Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:56 PM UTC